Lonza Group Ltd│ Muenchensteinerstrasse 38 │CH-4002 Basel │Switzerland +41 61 316 81 11 │ www.lonza.com │ [email protected]
MEDIA RELEASE
Lonza
3 ADC
Lonza & Karen Fallen (Head of Mammalian and Microbial Development and
Manufacturing)
ADC 11 IND 5 3
ADC
Lonza & Thomas Rohrer (Head of Commercial Development Bioconjugates)
Lonza Group Ltd│ Muenchensteinerstrasse 38 │CH-4002 Basel │Switzerland +41 61 316 81 11 │ www.lonza.com │ [email protected]
2019 7 24 ( ) – Lonza
3 (ADC)
12
Lonza 3
ADC FDA
(CDMO)
2
Lonza
( )
2020 Ibex™Solutions
(HPAPI)
cGMP
Lonza
Lonza Healthcare Continuum™
Lonza & Lonza
Lonza 1897 2018 100
15,500 2018
Lonza Group Ltd│ Muenchensteinerstrasse 38 │CH-4002 Basel │Switzerland +41 61 316 81 11 │ www.lonza.com │ [email protected]
55 CORE EBITDA 15 www.lonza.com
Dr. Kristin Koehler
Investor Relations
Lonza Group Ltd
Tel +41 61 316 8782
Dr. Sanna Fowler
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 8929
Lonza
SGX-ST Lonza SGXST
SGXST 217 751
Lonza Lonza
Lonza
Lonza Ltd. 2019 7 24
Lonza Expands Bioconjugation Facility and Announces Approval of Third Commercial ADC
